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ABSTRACT
During peritoneal dialysis (PD), mesothelial cells undergo mesothelial-to-mesenchymal transition (MMT), a
process associated with peritoneal-membrane dysfunction. Because TGF-1 can induce MMT, we evaluated
the efficacy of TGF-1-blocking peptides in modulating MMT and ameliorating peritoneal damage in a
mouse model of PD. Exposure of the peritoneum to PD fluid induced fibrosis, angiogenesis, functional
impairment, and the accumulation of fibroblasts. In addition to expressing fibroblast-specific protein-1
(FSP-1), some fibroblasts co-expressed cytokeratin, indicating their mesothelial origin. These intermediate-
phenotype (Cyto/FSP-1) fibroblasts had features of myofibroblasts with fibrogenic capacity. PD fluid
treatment triggered the appearance of CD31/FSP-1 and CD45/FSP-1 cells, suggesting that fibroblasts
also originate from endothelial cells and from cells recruited from bone marrow. Administration of blocking
peptides significantly ameliorated fibrosis and angiogenesis, improved peritoneal function, and reduced the
number of FSP-1 cells, especially in the Cyto/FSP-1 subpopulation. Conversely, overexpression of
TGF-1 in the peritoneumby adenovirus-mediated gene transfer led to amarked accumulation of fibroblasts,
most of which derived from the mesothelium. Taken together, these results demonstrate that TGF-1 drives
the peritoneal deterioration induced by dialysis fluid and highlights a role of TGF-1-mediated MMT in the
pathophysiology of peritoneal-membrane dysfunction.
J Am Soc Nephrol 22: ●●●–●●●, 2011. doi: 10.1681/ASN.2010111197
Peritoneal dialysis (PD) is an alternative treatment of
end-stage renal disease and is based on the use of the
peritoneum as a semipermeable membrane across
whichultrafiltration anddiffusion takeplace.1,2 Expo-
sure to nonphysiologic PD solutions and episodes of
infection cause damage to the peritoneal membrane,
which undergoes submesothelial fibrosis, angiogene-
sis, and hyalinizing vasculopathy.3–8 These morpho-
logic alterations are associated with increased rates of
small-solute transport and with ultrafiltration dys-
function of the peritoneal membrane.3,5–8 Inflamma-
tory cells and pathologic fibroblasts, especially myofi-
broblasts, are considered to bemainly responsible for
peritonealmembrane deterioration during long-term
PD.3,9,10 Peritoneal myofibroblastsmay have at least a
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dual origin: (1) from resident fibroblasts through an activation
process and (2) from the mesothelium via mesothelial-to-
mesenchymal transition (MMT).11,12 MMT is a complex process
that allowsmesothelial cells to invade the submesothelial compact
zone.3,13,14 Mesothelial cells that have undergone amyofibroblast
conversion acquire the capacity to synthesize extracellularmatrix
components aswell as pro-inflammatory andpro-angiogenic fac-
tors, thereby contributing to the deterioration of the peritoneal
membrane.15–18 Thepresenceofmesothelial cellswithmesenchy-
malphenotype, either in thePDeffluentor theperitoneal tissueof
PD patients, is correlated with high transport rates.15–18 In other
fibrotic disorders, myofibroblasts may also originate from the lo-
cal conversion of endothelial cells, through an endothelial-to-
mesenchymal transition (EnMT),19–21 and from bone-marrow-
derived circulating cells (fibrocytes) that are recruited to the
injured tissues.22–24 The presence of these myofibroblast sub-
populations in the damaged peritoneum and their contribution
to the fibrotic process induced by PD has not been described so
far.
TGF-1 is a prototypical inducer of epithelial-to-mesenchy-
mal transition in several tissues and organs.25–28 TGF-1 is also a
key factor for themyofibroblasticdifferentiationof resident fibro-
blasts and recruited fibrocytes and for the mesenchymal conver-
sion of endothelial cells via EnMT.20,24,29 TGF-1 binds to a spe-
cific type I serine-threonine kinase receptor and triggers different
Smad-dependent and Smad-independent signaling pathways,
which result in a profound molecular reprogramming including
the downregulation of the intercellular adhesionmolecule E-cad-
herin and theupregulationofmesenchymal-associatedmolecules
such as Snail, fibronectin, collagen I, and -smooth muscle actin
(-SMA).3,26,27
TGF-1 is considered a master molecule in the development
ofperitonealdysfunctionbecause itsoverexpressionhasbeencor-
relatedwithworsePDoutcomes.30–32The relevanceofTGF-1 in
peritoneal damage is further suggested in experimental animal
models in which the TGF-1 gene is transduced into the perito-
neal cavity with adenovirus vectors, recapitulating the structural
and functional alterations observed in PD patients.33–35 Overex-
pression ofmolecules counteractingTGF-1-triggered Smad sig-
naling, including Smad-7 and bonemorphogenic protein-7, pre-
vents and reverses PD fluid-induced peritoneal worsening.36–40
Furthermore, inhibition of TGF-1-induced Smad-independent
pathways ameliorates the peritonealmembrane alterations in dif-
ferent experimental models.41 However, the potential protective
effects for the peritoneal membrane of agents directly targeting
TGF-1 have not been explored.
In this study, we used two synthetic peptides (P17 and
P144) designed to directly bind TGF-1 and block its biologic
function and that have been demonstrated to act systemically
and to have robust antifibrotic effects in various organs such as
the liver, heart, and skin.42–45 We show that intraperitoneal
administration of these blocking peptides to mice exposed to
PD fluid preserved the peritoneal morphology and function
and decreased the accumulation of different subpopulations of
“fibroblast-specific protein-1” (FSP-1) fibroblasts, especially
of those co-expressing the mesothelial marker cytokeratin.
These cells with intermediate phenotype (Cyto/FSP-1) dis-
played myofibroblast-like characteristics including fibrogenic
capacity. These results point to TGF-1-mediated MMT as a
key process in the peritoneal damage induced by PD.
RESULTS
TGF-1-Blocking Peptide P17 Counteracts
TGF-1- and Effluent-Induced MMT In Vitro
First, we analyzed the effect of TGF-1-blocking peptide on
theMMTofmesothelial cells in vitro. Treatment of omentum-
derived mesothelial cells with TGF-1 and control peptide in-
duced the phosphorylation of Smad-2/3 and the expression of
Snail at early time points (6 hours) and downregulated the
expression of E-cadherin at 24 hours. These effects were pre-
vented by co-treatment with TGF-1-blocking peptide P17
(Figure 1, A and B). In addition, peptide P17 completely
blocked TGF-1-mediated upregulation of the mesenchymal
markers collagen I and fibronectin at 72 hours (Figure 1B).
These data were further confirmed with mesothelial cells ex-
posed to effluents from PD patients suffering peritonitis to
induce MMT (Figure 1C).
TGF-1-Blocking Peptides Ameliorate PD-Induced
Peritoneal Membrane Structural and Functional
Alterations
We analyzed whether the TGF-1-blocking peptides P17 and
P144 might prevent the deterioration of the peritoneal mem-
brane in amousemodel of PD fluid exposure. Histologic anal-
ysis of parietal peritoneum biopsies from animals exposed to
PD fluid (PDF group) showed a loss of the mesothelial cell
monolayer and an increase in the peritoneal membrane thick-
ness when compared with mice exposed to saline solution
(control group) (Figure 2, A and B). Administration of TGF-
1-blocking peptides to PD fluid-treatedmice (PDFP17 and
PDFP144 groups) significantly reduced the peritoneal thick-
ness and preserved themesothelium (Figure 2, A and B). These
data were confirmed by quantitative reverse-transcriptase
(RT)-PCR, using RNA samples extracted from some perito-
neal biopsies, to analyze the expression ofmesenchymalmark-
ers. Exposure to PD fluid provoked the upregulation of colla-
gen I, fibronectin, and -SMAmRNAs; treatment with P17 or
P144 interfered with the induction of these mesenchymal-as-
sociated molecules (Figure 2C). To determine the effect of PD
fluid exposure, with or without blocking peptides, on the ex-
pression of TGF-1, the levels of this cytokine were measured
in the effluents of the different groups. Exposure to PD fluid
sharply induced the production of TGF-1, and administra-
tion of P17 or P144 significantly reduced its concentrations,
suggesting the existence of a positive feedback in the peritoneal
expression of TGF-1 (Figure 2D). As shown in Figure 2E,
there was a correlation between submesothelial thickness and
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the expression of TGF-1, indicating that this cytokine played
a central role in peritoneal fibrosis.
To test the effect of blocking peptides on PD fluid-induced
angiogenesis, blood vessels of the parietal peritoneum were
stained with an anti-CD31 antibody. There was a significant
increase in the number of vessels in PD fluid-instilled mice
when compared with the control saline-treated mice, and ad-
ministration of peptides P17 or P144 to PD fluid-instilledmice
significantly reduced this angiogenesis (Figure 3, A and B). To
further explore the effects of TGF-1 blockade on angiogene-
sis, the effluent levels of vascular endothelial growth factor
(VEGF) were measured in the different experimental condi-
tions. PD fluid exposure strongly increased the concentration
of VEGF in the peritoneal cavity, and administration of pep-
tides P17 or P144 significantly reduced the levels of this factor
(Figure 3C). A correlation between vessel formation and the
production of VEGF was observed, reinforcing the notion of
the relevance of this growth factor in peritoneal angiogenesis
(Figure 3D).
To analyze the functional relevance of the observed mor-
phologic changes of the peritoneum, a peritoneal ultrafiltra-
tion test was performed on the last day of treatments. Mice of
the different groups were instilled with 2 ml of PD solution,
and 30 minutes later the total peritoneal volumes were recov-
ered. As shown in Figure 4A, the volumes recovered from PD
fluid-exposed animals were lower than those from saline-
treated mice, and a significant increase of the volumes recov-
ered was obtained in mice exposed to PD fluid that were ad-
ministered peptides P17 or P144. We observed that the loss of
ultrafiltration correlatedwith peritoneal thickness (Figure 4B),
angiogenesis (Figure 4C), and with the production of VEGF
(Figure 4D). These results demonstrated that the blockade of
Figure 1. TGF-1-blocking peptide P17 interferes with TGF-1- and effluent-induced MMT of mesothelial cells. Omentum-derived
mesothelial cells were treated for 6, 24, or 72 hours with TGF-1 (1 ng/ml) or effluents from patients that suffered from peritonitis in
the presence or absence of 150 g/ml of P17. (A) Immunofluorescence microscopy shows nuclear staining of phospho-Smad 2/3 in
TGF-1-treated mesothelial cells at 6 hours (middle panel). Mesothelial cells co-treated with TGF-1 and P17 (right panel) and
untreated cells (left panel) do not show phospho-Smad 2/3 staining. The experiment was repeated at least three times, and a
representative experiment is shown. Magnification: 200. (B and C) Quantitative RT-PCR shows that peptide P17 blocks TGF-1- and
effluent-mediated induction of Snail and prevents E-cadherin downregulation. P17 also blocks the upregulation of the MMT-associated
molecules collagen I and fibronectin. Bars depict mean  SEM of three independent experiments.
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Figure 2. Administration of TGF-1-blocking peptides P17 or P144 decreases PD-induced peritoneal membrane thickness in a mouse
model. Mice received a daily instillation of standard PD fluid for 5 weeks and intraperitoneally administered with control peptide (4
mg/kg per day: PDF, n 10), P17 (4 mg/kg per day: PDFP17, n 11), or P144 (4 mg/kg per day: PDFP144, n 11). A control group
of mice that were instilled with saline was also included (Control; n  7). Peritoneal samples were prepared and analyzed as described
in the Concise Methods. (A) Standard PD fluid exposure increases matrix deposition and the thickness of the peritoneal membrane,
whereas TGF-1-blocking peptide administration significantly reduces these effects when measured in Masson’s-trichrome-stained
sections (representative slides). Magnification: 200. (B) Box plots graphic represent 25th and 75th percentiles and median, minimum,
and maximum values of thickness (m). (C) Quantitative RT-PCR shows that PD fluid exposure upregulates the expression of the
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TGF-1 ameliorated the deleterious effects of PD fluid on the
peritoneum, reducing fibrosis and angiogenesis and ultimately
improving peritoneal membrane function.
TGF-1-Blocking Peptides Reduce the Accumulation of
FSP-1 Fibroblasts in Response to PD
Another characteristic histologic change of the peritoneal
membrane during PD is the accumulation of fibroblasts ex-
pressing FSP-1 in the submesothelial compact zone.39,46 In the
peritoneum from control saline-treatedmice, there was no ex-
pression of FSP-1. By contrast, FSP-1 fibroblasts were present
in the submesothelial compact region of mice treated with PD
fluid (Figure 5, A and B). A remarkable finding was the clus-
tering tendency of FSP-1 fibroblasts, mainly restricted to the
upper submesothelial area, but in some cases, especially those
with prominent fibrosis, FSP-1 fibroblasts also appeared in
the deeper compact zone (Figure 5A). PD fluid-instilled mice
treated with peptides P17 or P144 showed significant de-
creased submesothelial accumulation of FSP-1 fibroblasts
(Figure 5, A and B).
TGF-1-Blocking Peptides Exert a Major Effect on PD
Fluid-Induced MMT
To characterize the different subpopulations of pathologic
fibroblasts in the injured peritoneum during PD fluid expo-
sure, two-color immunofluorescence analysis was per-
formed using the anti-FSP-1 antibody in conjunction with
antibodies against cytokeratin (mesothelial marker), CD45
(pan-leukocyte marker expressed by fibrocytes), or CD31
(endothelial marker). As expected, in the peritoneum from
control mice the expression of cytokeratin was exclusively
restricted to the preserved mesothelium (Supplemental Fig-
ure S1) and the expression of CD31 was confined to deeper
vessels located in the muscular tissue (Figure 3 and Supple-
mental Figure S1). Furthermore, in the control peritoneum
there was no expression of FSP-1 (Figure 5 and Supplemen-
tal Figure S1) and CD45 cells were barely detected (Sup-
plemental Figure S1). In the peritoneal tissue of PD fluid-
instilled mice there was accumulation of FSP-1 fibroblasts,
and different numbers of these fibroblasts co-expressed cy-
tokeratin (Figure 6, A and B), CD45 (Figure 7, A and B), or
CD31 (Figure 8, A and B). The most abundant subpopula-
tions, in terms of number per field, were those co-express-
ing Cyto/FSP-1 and CD45/FSP-1, whereas only a few
fibroblasts were CD31/FSP-1 (Figure 9A). The average
percentages of the different subpopulations of activated fi-
broblasts were 37% for Cyto/FSP-1, 34% for CD45/
FSP-1, and 5% for CD31/FSP-1 (Figure 9B). The re-
maining 24% were single positive for FSP-1 (Figure 9B).
Administration of peptides P17 or P144 to PD fluid-treated
mice significantly reduced the number per field of Cyto/
FSP-1 (Figure 6, A and B), CD45/FSP-1 (Figure 7, A and
B), and CD31/FSP-1 (Figure 8, A and B). Of note, the num-
ber of fibroblasts single positive for FSP-1 did not change upon
blocking peptide administration (Figure 9A and Supplemental
Figure S2). Proportionally, the most prominent reduction by
the blocking peptides was observed in the Cyto/FSP-1 sub-
population (Figure 9, A and B), suggesting a major effect of
TGF-1 on the generation of pathologic fibroblasts through
the mesenchymal conversion of mesothelial cells.
Cells with Intermediate Phenotype (Cyto/FSP-1)
Possess Features of Myofibroblasts and Fibrogenic
Capacity
To analyze if myofibroblasts may derive frommesothelial cells in
the injured peritoneum, a two-color immunofluorescence analy-
sis was performed using the anti--SMA and anti-cytokeratin
antibodies. Exposure to PD fluid induced the accumulation of
Cyto/-SMA fibroblasts, and administration of peptides P17
or P144 significantly reduced the number of this myofibroblast
subpopulation(SupplementalFigureS3).Thenumberper fieldof
Cyto/-SMA fibroblasts, in each experimental condition, was
approximately one half of the Cyto/FSP-1 subpopulation
(Supplemental Figure S3). By using three-color immunofluores-
cence analysis, we estimated that approximately 50% of Cyto/
FSP-1 fibroblasts co-expressed -SMA (data not shown).
To furtherdemonstrate thepathologicnatureof the fibroblasts
with intermediate phenotype (Cyto/FSP-1), the capacity of
these cells to produce extracellular matrix components was ex-
plored in cell culture experiments.Kinetic analysis of extracellular
matrix component synthesis, duringMMT in vitro, demonstrated
that the upregulation of fibronectin and collagen I started at 48
hours and remained until the last day (Figure 10A and data not
shown).Three-color immunofluorescenceanalysisofmesothelial
cells treated with TGF-1 for 72 hours showed that almost all
fibronectin-expressing cells were Cyto/FSP-1 (Figure 10B).
TGF-1-blocking peptide P17 prevented the induction of FSP-1
and fibronectin (Figure 10B). Similarly, triple staining of effluent-
derived mesothelial cells with no epitheliod phenotype showed
that the most abundant fibronectin-producing cell population
was Cyto/FSP-1 and only a small proportion of the cells were
Cytoneg/FSP-1 (Figure 10C). These results indicated that the cell
with intermediate phenotype (Cyto/FSP-1) had already ac-
quired fibrogenic capacity.
mesenchymal marker -SMA, collagen I, and fibronectin. TGF-1-blocking peptide administration reduces these effects. Bars depict
mean  SEM. (D) Measurement of TGF-1 in the drained volumes shows an increase of this growth factor in PD fluid-instilled animals.
Administration of TGF-1-blocking peptides significantly reduces TGF-1 production. Box plots are depicted as picograms per milliliter
(pg/ml) and represent the median, minimum, and maximum values as well as the 25th and 75th percentiles. Numbers above boxes
depict mean  SEM. Symbols represent the statistical differences between groups. (E) Correlation between thickness (m) and TGF-1
levels (pg/ml) in the whole group of mice (Spearman regression, P  0.0004; n  39).
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Overexpression of TGF-1 Induces the Peritoneal
Accumulation of FSP-1 Fibroblasts, Most of Which
Co-Express Cytokeratin
In previous studies, it was shown that TGF-1 overexpression
reproduced the structural and functional alterations of the
peritoneum observed in PD patients and that MMT appeared
during the early stages (days 4 to 7) of peritoneal damage.33–35
To characterize the different subpopula-
tions of activated fibroblasts in response to
TGF-1 overexpression, adenovirus-me-
diated gene transfer experiments were car-
ried out. Mice were infected with control
adenovirus or adenovirus encoding active
TGF-1 by intraperitoneal injection. Ani-
mals were killed on day 4 after infection.
Parietal peritoneal sections were subjected
to dual staining using anti-FSP-1 antibody
in conjunction with antibodies against cy-
tokeratin, CD45 or CD31.
As expected, mice infected with control
adenovirus showed normal peritoneal his-
tology with a mesothelial cell monolayer, a
thin submesothelial compact zone, and few
vessels located in the muscular tissue. Fur-
thermore, the expression of FSP-1 in these
control mice was absent and the expression
of CD45 was barely detected (Supplemen-
tal Figure S4). In contrast, mice infected
with adenovirus harboring TGF-1 showed
loss of the mesothelial cell monolayer, a fi-
broproliferative response, and a strong ac-
cumulationofFSP-1 fibroblasts (Figure11A).
Importantly, the most abundant subpopu-
lation of FSP-1 fibroblasts was that co-
expressing Cyto/FSP-1 (Figure 11, A
and B), representing approximately 64% of
the activated fibroblasts (Figure 11C).
There was also a relevant accumulation of
CD45/FSP-1 cells (Figure 11, A and B),
with an average percentage of 29% (Figure
11C), whereas single-positive FSP-1 and
CD31/FSP-1 fibroblasts were only mar-
ginally represented (Figure 11C). These re-
sults further demonstrated that TGF-1
exerted a major effect on mesothelial cells,
which through the MMT process consti-
tuted the main source of pathologic fibro-
blasts in the injured peritoneum.
DISCUSSION
During the last few years it has been spec-
ulated that the MMT of mesothelial cells
might be a potential target for therapeu-
tic intervention to preserve peritoneal morphology and
function.3,9,10 In the complex microenvironment that oc-
curs during PD fluid-induced tissue injury a wide range of
cytokines and factors are upregulated, making it difficult to
assign priorities or hierarchy for their effects on MMT and
on the onset and progression of peritoneal damage.3,10
Nonetheless, TGF-1 has been proposed to be a key mole-
Figure 3. Treatments with TGF-1-blocking peptides P17 or P144 decrease PD-
induced angiogenesis and inhibit VEGF production. Mice received a daily instillation of
standard PD fluid for 5 weeks and intraperitoneally administered with control peptide
(PDF, n  10), P17 (PDFP17, n  11), or P144 (PDFP144, n  11). A control group
of mice that were instilled with saline was also included (Control; n  7). (A) Standard
PD fluid exposure increases peritoneal angiogenesis and TGF-1-blocking peptide
administration significantly reduces the number of vessels, as determined by CD31
staining (representative slides). (B) Box plots represent the median, minimum, and
maximum values as well as the 25th and 75th percentiles. Numbers above boxes
depict mean  SEM of CD31 staining. Symbols represent the statistical differences
between groups. Magnification: 200. (C) Analysis of VEGF in the drained volumes
shows a strong increase of this growth factor in PD fluid-instilled animals, and admin-
istration of TGF-1-blocking peptides significantly reduces VEGF production. Box
plots are depicted as picograms per milliliter and represent the median, minimum, and
maximum values as well as the 25th and 75th percentiles. Numbers above boxes
depict mean  SEM of VEGF levels. Symbols represent the statistical differences
between groups. (D) Correlation between angiogenesis (CD31 staining) and VEGF
levels (pg/ml) in the whole group of mice (Spearman regression, P  0.0001; n  39).
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cule in PD fluid-induced peritoneal membrane deteriora-
tion.30–41
In this study, we demonstrate that administration of two
TGF-1-blocking peptides to mice exposed to PD fluid signif-
icantly decreases peritoneal fibrosis and angiogenesis, partially
preserves membrane function, and significantly blocks the ac-
cumulation of FSP-1 and -SMA fibroblasts. We have pre-
viously shown that in response to PD, the pathologic fibro-
blasts may originate from resident fibroblasts and from the
mesothelium via MMT.11,12,39,46 Herein, we provide evidence
for the first time that peritoneal FSP-1 fibroblasts may also
derive from bone-marrow-derived circulating cells (CD45)
and from the local conversion of endothelial cells (CD31) via
EnMT. The percentage of mesothelial-cell-derived FSP-1 fi-
broblasts, 37%, in the injured peritoneum is in agreement with
that found in renal fibrosis, in which approximately 36% come
from local conversion of tubular epithelial cells via epithelial-
to-mesenchymal transition.22 In contrast, the percentages of
FSP-1 fibroblasts deriving from circulating CD45 cells and
from endothelial cells in the PD-fluid-exposed peritoneum
differ sharply from those observed in the
fibrotic kidney. Whereas in renal fibrogen-
esis approximately 14% to 15% of patho-
logic fibroblasts derive from bone-marrow
CD45 cells22,23 and 30% to 50% from
CD31 endothelial cells,19 in the injured
peritoneumwe have estimated percentages
of 34% and 5% for the CD45/FSP-1 and
CD31/FSP-1 subpopulations, respec-
tively. These divergent observations may
suggest that tissue- and organ-specific mi-
croenvironments dictate the different pro-
portions of pathologic fibroblast sub-
populations. Furthermore, it might be
speculated that the contribution of the dif-
ferent fibroblast subpopulations to the
peritoneal structural and functional deteri-
oration is not necessarily dependent on
their relative abundance. In this sense, we
have observed that the most abundant
Cyto/FSP-1 subpopulation correlates
with peritoneal fibrosis better than the
other subpopulations (Supplemental Fig-
ure S5), whereas the less representative
CD31/FSP-1 subpopulation shows the
strongest correlation with the loss of ultra-
filtration (Supplemental Figure S6). The fi-
broblasts single positive for FSP-1, which
represented up to 24%, correlate neither
with peritoneal fibrosis nor with the loss of
ultrafiltration (Supplemental Figures S5
and S6). The origin of these FSP-1 single-
positive cells is not fully clear: They might
derive from resident fibroblasts or from other
fibroblast subpopulations (e.g., Cyto/FSP-1
after losing the expression of cytokeratins). It is worthwhile to
note thatmyofibroblasts are commonly observed in peritoneal
biopsies from PD patients.12,14 Nevertheless, the heteroge-
neous origin of these myofibroblasts and their roles in the set-
ting and progression of different features related with perito-
neal deterioration have not been explored in depth. Only a few
studies have been carried out with PD patients, which have
shown significant correlations among high peritoneal trans-
port rates and the presence of MMT-derived fibroblasts in the
effluents or in peritoneal tissue specimens.15–18
TGF-1 is a strong inducer ofMMT and EnMT3,11,13–16,20,21
and appears to be a key factor for the myofibroblastic differen-
tiation of resident fibroblasts and recruited fibrocytes.23,24,29 In
this study, we show that administration of two different TGF-
1-blocking peptides to PD fluid-treatedmice significantly re-
duced the number of fibroblasts of all subpopulations except of
those being FSP-1 single positive. One important finding is
that the most prominent reduction by the blocking peptides is
exerted on the Cyto/FSP-1 subpopulation, suggesting that
the MMT process is tightly regulated by TGF-1 levels in the
Figure 4. - TGF-1-blocking peptide P17 or P144 treatments improve peritoneal
ultrafiltration. A 30-minute ultrafiltration test was performed on the last day of treat-
ments. (A) The volumes recovered from animals exposed to PD fluid (PDF; n  10) are
lower than those from mice instilled with saline solution (Control; n  7), and an
increase of net ultrafiltration is obtained in mice exposed to PD fluid that were
administered P17 (PDFP17; n 11) or P144 (PDFP144; n 11). Box plots represent
25th and 75th percentiles and median, minimum, and maximum values. Numbers
above boxes depict mean  SEM. Symbols represent the statistical differences be-
tween groups. (B to D) Correlations between ultrafiltration and peritoneal thickness
(m), angiogenesis (CD31 staining), and VEGF levels (pg/ml) in the whole group of
mice (Spearman regression, n  39).
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context of PD fluid exposure. This hypothesis is reinforced by
the fact that TGF-1 overexpression results in a stronger accu-
mulation of Cyto/FSP-1 fibroblasts than any other subpop-
ulation of fibroblasts; however, it cannot be ruled out that this
effect could be due to a better accessibility of mesothelial cells
to TGF-1 than any other peritoneal cell. Furthermore, in vitro
cell culture experiments demonstrate that treatment of meso-
thelial cells with blocking peptide prevents the MMT induced
by TGF-1 and by PD effluents.
We are aware that agents directly blocking TGF-1 cannot
be easily used in the clinical practice of PD, at least for long-
Figure 5. TGF-1-blocking peptides reduce the number of
FSP-1 fibroblasts in the compact zone of the parietal perito-
neum. (A) Immunofluorescence microscopy analysis of parietal
peritoneal tissue sections stained for FSP-1 (red) with 4,6-di-
amidino-2-phenylindole (DAPI) counterstaining shows accumula-
tion of FSP-1 fibroblasts in the submesothelial space in the PDF
group (n  10), and the administration of P17 or P144 peptides
reduces the number of FSP-1 cells per field (PDFP17, n  11;
PDFP144, n  11). The expression of FSP-1 is absent in animals
instilled with saline (Control, n  7). Representative pictures are
presented. Magnification:200. (B) The reductions in the number
of FSP-1 fibroblasts by P17 or P144 peptides are significant. Box
plots represent 25th and 75th percentiles and median, minimum,
and maximum values. Numbers above boxes depict mean 
SEM. Symbols show statistical differences between groups.
Figure 6. TGF-1-blocking peptides reduce the number of fibro-
blasts derived from mesothelial cells. (A) Immunofluorescence
microscopy analysis of parietal peritoneal sections stained for
cytokeratin (green) and FSP-1 (red) with DAPI counterstaining
shows accumulation of transdifferentiated mesothelial cells in the
submesothelial space (cytokeratin positive cells) in the PDF group
(n  10), some of which co-express FSP-1 (yellow cells in the
Merge panel). The administration of P17 or P144 peptides re-
duces the number of cytokeratin/FSP-1 double-positive cells per
field (PDFP17, n  11; PDFP144, n  11). Representative
slides are presented. Magnification: 200. Arrows show exam-
ples of double-positive cells. (B) The reductions in the number of
cytokeratin/FSP-1-positive fibroblasts by P17 or P144 peptides
are significant. Box plots represent 25th and 75th percentiles and
median, minimum, and maximum values. Numbers above boxes
depict mean  SEM. Symbols show statistical differences be-
tween groups.
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term treatments, because TGF-1 has important modulating
functions of the immune and inflammatory responses.47,48 It
can be expected that further molecular studies of the TGF-1
signaling pathways involved in themesenchymal conversion of
mesothelial cells will provide more specific strategies for the
preservation of the peritoneal membrane with minimum side
effects.
CONCISE METHODS
Peptides and Adenoviral Vectors
P17 is a small 15-mer peptide (KRIWFIPRSSWYERA) that was iden-
tified to bind TGF-1 using a phage-displayed peptide library and
demonstrated to block the activity of TGF-1 in vitro and in vivo.42
P144 is a synthetic 14-mer peptide designed from the TGF-1 type III
receptor (TSLDASIIWAMMQN) that has been shown to bind
TGF-1 and to inhibit its activity in vitro and in vivo.43,44 As a control,
Figure 7. TGF-1-blocking peptides reduce the number of fibro-
blasts derived from bone-marrow-recruited cells. (A) Immunoflu-
orescence microscopy analysis of parietal peritoneal biopsies
stained for CD45 (green) and FSP-1 (red) with DAPI counterstain-
ing shows the recruitment of circulating leukocytes in the PDF
group (n  10), some of which co-express FSP-1 (yellow cells in
the Merge panel). The administration of P17 or P144 peptides
reduces the number of CD45/FSP-1 double-positive cells per field
(PDFP17, n  11; PDFP144, n  11). Representative pictures
are presented. Magnification: 200. (B) The reductions in the
number of CD45/FSP-1-positive fibroblasts by P17 or P144 pep-
tides are significant. Box plots represent 25th and 75th percen-
tiles and median, minimum, and maximum values. Numbers
above boxes depict mean  SEM. Symbols show statistical dif-
ferences between groups.
Figure 8. TGF-1-blocking peptides reduce the number of fibro-
blasts derived from endothelial cells. (A) Immunofluorescence
microscopy analysis of parietal peritoneal samples stained for
CD31 (green) and FSP-1 (red) with DAPI counterstaining shows
the appearance of CD31/FSP-1 double-positive cells in the PDF
group (n  10). The administration of P17 or P144 peptides
reduces the number of CD31/FSP-1 double-positive cells per field
(PDFP17, n  11; PDFP144, n  11). Representative pictures
are presented. Magnification: 200. (B) The reductions in the
number of CD31/FSP-1-positive fibroblasts by P17 or P144 pep-
tides are significant. Box plots represent 25th and 75th percen-
tiles and median, minimum, and maximum values. Numbers
above boxes depict mean  SEM. Symbols show statistical dif-
ferences between groups.
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we used the irrelevant 14-mer peptide SVSRARPRLLLLGL designed
fromtheNS5BproteinofhepatitisCvirusgenotype2a(aminoacids3005
to 3018). P17, P144, and control peptides were synthesized by the F-moc
solid-phasemethod as describedpreviously.42 The purity of peptideswas
at least 95% as judged byHPLC. The adenoviral vector expressing active
TGF-1 was kindly provided by David Dichek, (University ofWashing-
ton, Seattle) and has been previously described.49
Culture of Mesothelial Cells and Treatments
Mesothelial cells were obtained from omentum samples and from PD
effluents using themethodsdescribedpreviously.15,16Cellswere cultured
in Earle’s M199 medium supplemented with 20% fetal calf serum, 50
U/ml penicillin, 50 g/ml streptomycin, and 2% Biogro-2 (Biologic In-
dustries, Israel). The purity of effluent and omentum-derived mesothe-
lial cell cultures was determined by the expression of the standardmeso-
thelial markers intercellular adhesion molecule-1, cytokeratins, and
calretinin. The study presented here is adjusted to the Declaration of
Helsinki and was approved by the Ethics Committee of the Hospital
Universitario de la Princesa (Madrid, Spain). Written consent was ob-
tained fromthePDpatients included in this study touseeffluent samples.
Verbal informed consent was obtained fromomentumdonors that sub-
mitted to elective surgeries.
To induceMMT in vitro, omentum-derivedmesothelial cells were
seeded onwells coated with 50g/ml of collagen I (Roche Boehringer
GmbH, Mannheim, Germany) and treated for different time periods
(6 hours to 6 days) with human-recombinant TGF-1 (1 ng/ml; R&D
Systems, Inc., Minneapolis, MN) or with effluents from PD patients
suffering episodes of peritonitis diluted one half with culture me-
dium. These treatments are proven to be good in vitro models of
MMT.11,16,39,46 When indicated, TGF-1-blocking peptide P17 was
used at a final concentration of 150 g/ml. This dose of P17 was
similar to that used in previous studies.42–45
For quantitative RT-PCR analysis, mesothelial cells were lysed in
TRI reagent (Ambion, Inc., Austin, TX), and RNA was extracted as
per fabricant instructions. Complementary DNA was synthesized
from 2 g of total RNA by reverse transcription (RNA PCR Core Kit,
Applied Biosystems, Inc.). Real time-PCR was carried out in a Light
Cycler 480 (RocheDiagnostics GmbH,Mannheim,Germany) using a
SYBRGreen Kit (Roche Diagnostics GmbH) and specific primers sets
for Snail, E-cadherin, collagen I, and fibronectin (Supplemental Table
S1). Primers specific for histone H3 were used as a control.
Mesothelial cells were stained for immunofluorescence analysis
with antibodies against phosphorylated-Smad 2/3 (Santa Cruz Bio-
technology, Santa Cruz, CA), pan-cytokeratin (Sigma-Aldrich, St
Louis, MO), FSP-1 (Dako, Glostrup, Denmark), and fibronectin
(Novus Biologicals, Littleton, CO). The cells were fixed in 4% form-
aldehyde in PBS and blocked with 10%horse serum in PBSwith 0.3%
Triton X-100. Cells and antibodies were first incubated in PBS with
0.1% Triton X-100 overnight at 4°C. After three washing steps (5
minutes in PBS with 0.1% Triton X-100), secondary Alexa-labeled
antibodies were incubated with cells for 90 minutes at room temper-
ature. Negative controls for immunofluorescence staining were con-
Figure 9. Relative effects of TGF-1-blocking peptides on the different subpopulations of fibroblasts. (A) Box plot graphics represent
25th and 75th percentiles and median, minimum, and maximum of the numbers of pathologic fibroblasts from different origin in the
PDF, PDFP17, and PDFP144 groups. (B) Circles depict the average percentages of the different subpopulations of fibroblasts in the
PDF, PDFP17, and PDFP144 groups.
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ducted using 10% rabbit serum instead of primary antibody. Images
were analyzed by computerized digital image analysis (AnalySIS, Soft
Imaging System).
PD Fluid Exposure Model in Mice
A total of 44 female C57BL/6 mice between 12 and 16 weeks of age
were used in this study (Harlan Interfauna Iberica, Barcelona,
Spain). The experimental protocol used was in accordance with
the National Institutes of Health Guide for
Care and Use of Laboratory Animals and was
approved by the Animal Ethics Committee of
the Unidad de Cirugía Experimental of the
Hospital Universitario la Paz. PD fluid or sa-
line solution were instilled via a peritoneal
catheter connected to an implanted subcuta-
neous mini access port (Access Technologies,
Skokie, IL) as described previously.16,46,50
During the first week after surgery, the ani-
mals implanted with a peritoneal access port
(n 44) received 0.2 ml of saline with 1 IU/ml
of heparin to facilitate wound healing. There-
after, during a 5-week period, 8 mice were
daily instilled with 1.5 ml of saline solution
(control; n  8), 12 mice were daily instilled
with 1.5 ml of standard PD fluid composed of
4.25% glucose and buffered with lactate (Stay
Safe, Fresenius, Bad Homburg, Germany) and
treated with control peptide (4 mg/kg per day;
PDF group), 12 mice were daily instilled with
1.5 ml of standard PD fluid and treated with
P17 (4 mg/kg per day; PDFP17 group), and
12 mice were daily instilled with 1.5 ml of
standard PD fluid and treated with P144 (4
mg/kg per day; PDFP144 group). The doses
of P17 and P144 used in this study were sim-
ilar to those used previously.42–44,51 Two ani-
mals of the PDF group and one in each of the
others groups were not used in the final anal-
ysis, with the main causes of dropouts being
catheter port infection or traumatic catheter
removal (control group, n  7; PDF group,
n 10; PDFP17 group, n 11; PDFP144
group, n  11). A peritoneal equilibrium test
was performed during the last day of treat-
ments. All of the mice were instilled with 2 ml
of PD solution, and animals were anesthetized
with isoflurane (MTC Pharmaceuticals, Cam-
bridge, Ontario, Canada) 30minutes later and
sacrificed to recover the total peritoneal vol-
umes. Parietal peritoneum samples were ob-
tained from the contralateral side of the im-
planted catheter. Some of these samples
(control group, n  5; PDF group, n  6;
PDFP17, n  7; PDFP144, n  7) were
used for peritoneal RNA extraction. Food and
water were provided ad libitum to the animals
during the experiment.
Overexpression of TGF-1 in the Peritoneum by
Adenovirus-Mediated Gene Transfer
Eight female C57BL/6 mice (12 and 16 weeks old) were used in this
experiment (Harlan Interfauna Iberica). The experimental protocol
used was in accordance with the National Institutes of Health Guide
Figure 10. Cells with intermediate phenotype (Cyto/FSP-1) have fibrogenic capac-
ity. (A) Quantitative RT-PCR shows that fibronectin is upregulated in mesothelial cells
stimulated with TGF-1 after 48 hours of treatment. (B) Immunofluorescence micros-
copy shows that almost all mesothelial cells treated with TGF-1 for 72 hours are
positive for cytokeratin (green), FSP-1 (red), and fibronectin (blue). Control cells and
cells co-treated with TGF-1 and peptide P17 are only positive for cytokeratin. (C)
Triple immunofluorescence analysis of effluent-derived mesothelial cells with no epi-
theliod phenotype shows that the most abundant fibronectin-producing cells are
positive for cytokeratin and FSP-1. However, a small proportion of fibronectin-produc-
ing FSP-1 cells are negative for cytokeratin (arrow inMerge panel). Magnification: 400.
BASIC RESEARCHwww.jasn.org
J Am Soc Nephrol 22: ●●●–●●●, 2011 TGF-1-Blocking Peptides and Peritoneal Damage 11
for Care and Use of Laboratory Animals and was approved by the
Animal Ethics Committee of the Unidad de Cirugía Experimental of
theHospital Universitario la Paz.Micewere injected intraperitoneally
with 100 l of suspensions containing 1 108 plaque-forming units
of an adenovirus expressing active TGF-1 (n 5) or 1 108 plaque-
forming units of the empty adenoviral vector that served as a control
(n 3). Food and water were provided ad libitum. Four days after the
injection, animals were anesthetized with isoflurane (MTC Pharma-
ceuticals) and sacrificed. The parietal peritoneum of all animals was
collected for histologic and immunofluorescence analysis.
Morphologic Analysis of Peritoneal
Samples, Quantitative PCR, and
Effluent Growth Factor
Measurements
For histologic analyses, specimens of the pari-
etal peritoneum were obtained from the con-
tralateral side to the tip of the implanted cathe-
ter. Cryostat sections (5 m) were cut and
stained with Masson’s trichrome (Merck,
Darmstadt, Germany) to quantify fibrosis. The
thickness of submesothelial tissue was deter-
mined by blinded microscope analysis using a
metric ocular and was expressed as the mean of
ten independentmeasurements for each animal.
For quantitative RT-PCR analysis of peritoneal
mesenchymalmarkers, frozen peritoneal tissues
were homogenized for total RNA extraction in
TRI reagent using a Polytron homogenizer.
Complementary DNA was synthesized from 2
g of total RNA by reverse transcription. Real-
time PCR was carried out in a Light Cycler 480
using a SYBR Green Kit (Roche Diagnostics
GmbH) and specific primers sets for -SMA,
collagen I, and fibronectin (Supplemental Table
S1). Primers specific for 18S RNAwere used as a
control.
Frozen sections were stained for immuno-
fluorescence analysis with antibodies to visual-
ize vasculature (CD31; Serotec, Oxford, United
Kingdom), mesothelial cells (pan-cytokeratin;
Sigma-Aldrich), bone-marrow-derived cells
(CD45; BDBiosciences Franklin Lakes, NJ), and
pathologic fibroblasts (FSP-1; Dako or -SMA;
Abcam, Inc., Cambridge, United Kingdom).
The frozen sections were fixed for 15minutes in
4% formaldehyde in PBS, and blockedwith 10%
horse serum for 60 minutes in PBS with 0.3%
Triton X-100. Sections and antibodies were first
incubated in PBS with 0.1% Triton X-100 over-
night at 4°C. After three washing steps, second-
ary Alexa-labeled antibodies and sections were
incubated for 90 minutes at room temperature.
After another washing process, the preparations
were mounted with a 4,6-diamidino-2-phe-
nylindole (DAPI) nuclear stain (Vectashield;
Vector Laboratories). Negative controls for im-
munofluorescence staining were conducted using 10% rabbit serum
instead of primary antibody. Images were analyzed by computerized
digital image analysis (AnalySIS, Soft Imaging System). The number
of cells with single- or double-positive staining was counted and was
expressed as the mean of ten independent measurements for each
animal. The amounts of VEGF andTGF-1 in the peritoneal effluents
were determined by ELISA-based assays according to the manufac-
turers instructions (PeproTech, Rocky Hill, NJ; Invitrogen Corpora-
tion; Carlsbad, CA).
Figure 11. Overexpression of TGF-1 in the peritoneum induces the accumulation of
FSP-1 fibroblasts, most of which derive from mesothelial cells. Mice were infected
with adenovirus encoding active TGF-1 by intraperitoneal injection, and animals were
killed on day 4 after infection. (A) Parietal peritoneal sections were subjected to dual
immunofluorescence analysis using anti-FSP-1 antibody (red) in conjunction with anti-
bodies against cytokeratin, CD45, or CD31 (green). A strong accumulation of cytoker-
atin/FSP-1 double-positive fibroblasts is observed (yellow cells in the Merge panel).
Representative slides are presented. Magnification: 200. (B) Box plot graphics rep-
resent 25th and 75th percentiles and median, minimum, and maximum of the numbers
of fibroblasts from different subpopulations. (C) Circle depicts the average percent-
ages of the different subpopulations of fibroblasts.
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Statistical Analysis
Results are presented as 25th and 75th percentiles; median, mini-
mum, andmaximumvalues in box plot graphics; and asmean SEM
in bar graphics. In Figures 9 and 11 the percentages were calculated
using the median of each fibroblast subpopulation. The data groups
were compared with the nonparametric Mann–Whitney rank sum
U-test and linear correlations were determined by Spearman regres-
sion using the SPSS statistic package version 14.5 (Chicago, IL) and
GraphPad Prism version 4.0 (La Jolla, CA). P 0.05 was considered
statistically significant.
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